Smith & Nephew plc (LON:SN – Get Free Report) insider Sybella Stanley purchased 3,810 shares of the business’s stock in a transaction dated Wednesday, March 26th. The stock was bought at an average cost of GBX 1,101 ($14.25) per share, for a total transaction of £41,948.10 ($54,294.72).
Smith & Nephew Stock Performance
Shares of LON SN opened at GBX 1,067 ($13.81) on Friday. The company has a debt-to-equity ratio of 70.22, a quick ratio of 0.84 and a current ratio of 2.51. The firm has a market capitalization of £11.70 billion, a PE ratio of 38.42, a P/E/G ratio of 0.46 and a beta of 0.62. The firm’s 50-day moving average price is GBX 1,070.03 and its 200 day moving average price is GBX 1,052.57.
Smith & Nephew Increases Dividend
The company also recently declared a dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Thursday, March 27th will be issued a $0.23 dividend. This is a positive change from Smith & Nephew’s previous dividend of $0.14. The ex-dividend date is Thursday, March 27th. This represents a dividend yield of 1.61%. Smith & Nephew’s payout ratio is 104.41%.
Wall Street Analysts Forecast Growth
Get Our Latest Stock Report on Smith & Nephew
Smith & Nephew Company Profile
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Featured Articles
- Five stocks we like better than Smith & Nephew
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback
- Top Biotech Stocks: Exploring Innovation Opportunities
- JPMorgan: The ‘NVIDIA of Banking’ Poised for More Gains?
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Buy the Chewy Stock Reversal? Here’s Why Now Is the Time
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.